Pancreatic cancer has been termed as the fifth most deadly types of cancer, claiming the lives of almost 7,900 people each year in the UK. In majority of the cases, the disease is diagnosed only after it has affected most of the body organs.

Further, only 3% of the sufferers are able to survive up to five years after being diagnosed of the cancer type. Despite, the funds diverted towards the research of the cancer is less, in comparison to those granted towards breast and prostate cancer research, due to which 11,600 and 10,700 people die each year.

Pancreatic Cancer UK highlighted that the funding granted for the disease is short. The charity aims at doubling the spending on the research of the disease by 2050, it wants it to be £10 million a year, which would then be approximately the same spent on bowel cancer and prostate cancer researches.

Alex Ford, Chief Executive, said: "We are committed to working with others to double survival rates for pancreatic cancer patients in the UK. We strongly believe there needs to be significant and sustained investment in research into the disease".

The charity emphasized that investments made in the research for the cancer have been low since the past several years, as a result of which the survival rates associated with the cancer are even low.